Defining Circadian Metabolism in Non-alcoholic Fatty Liver Disease (DECIMAL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jeremy Tomlinson
- Phone Number: 01865 857359
- Email: jeremy.tomlinson@ocdem.ox.ac.uk
Study Locations
-
-
-
Oxford, United Kingdom
- Recruiting
- University of Oxford
-
Contact:
- Jeremy W Tomlinson, MD PhD
- Phone Number: 44(0)1865 857359
- Email: jeremy.tomlinson@ocdem.ox.ac.uk
-
Contact:
- Leanne Hodson, PhD
- Email: leanne.hodson@ocdem.ox.ac.uk
-
Sub-Investigator:
- Thomas Marjot, MD
-
Sub-Investigator:
- Leanne Hodson, MD
-
Sub-Investigator:
- David Ray, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
NAFLD participants Confirmed by transient elastography (TE) with controlled attenuation parameter (CAP) ≥306 dB/m
Non-NAFLD Confirmed by transient elastography (TE) with controlled attenuation parameter (CAP) ≤215 dB/m
Description
Inclusion Criteria:
- Male or female
- BMI 25-50 kg/m2
- Age 18-75 years
Exclusion Criteria:
- A diagnosis of type 1 diabetes
- Type 2 diabetes controlled with medications other than metformin (within last 3 months)
- Shift working patterns in last 3-months or if likely to work shifts during study period.
- Current or recent (<3-months) use of weight loss medications
- Current or recent use of oral contraceptive pill or hormone replacement therapy (within last 3-months)
- Pregnancy
- A blood haemoglobin <120mg/dL
- History of alcoholism or a greater than recommended alcohol intake (Recommendations > 21 units on average per week for men and > 14 units on average per week for women)
- Haemorrhagic disorders
- Treatment with anticoagulant agents
- Other co-morbidities that in the eyes of the investigators may affect data collection
- Any medical condition in the opinion of the investigator that might impact upon safety or validity of the results
- Transient elastography (TE) controlled attenuation parameter (CAP) of between 216-305 dB/m
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NAFLD
|
Commercially available lifestyle and weight loss intervention
|
|
Controls (non-NAFLD)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in hepatic fatty acid synthesis as measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) between morning and evening
Time Frame: 12 hours
|
12 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference in morning and evening glucose production and disposal (of a labelled stable isotope tracer) during a two-step hyperinsulinaemic-euglycaemic clamp
Time Frame: 12 hours
|
12 hours
|
|
Difference in morning and evening glucose oxidation measured by incorporation of 13C in breath CO2 across a 2-step hyperinsulinemia euglycaemic clamp
Time Frame: 12 hours
|
12 hours
|
|
Changes in diurnal patterns of hepatic fatty acid synthesis after weight loss programme (measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG)
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15296
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.